Risk of SARS-CoV-2 Reinfection 18 Months After Primary Infection: Population-Level Observational Study
- PMID: 35586006
- PMCID: PMC9108359
- DOI: 10.3389/fpubh.2022.884121
Risk of SARS-CoV-2 Reinfection 18 Months After Primary Infection: Population-Level Observational Study
Abstract
Current data suggest that SARS-CoV-2 reinfections are rare. Uncertainties remain, however, on the duration of the natural immunity, its protection against Omicron variant, and on the impact of vaccination to reduce reinfection rates. In this retrospective cohort analysis of the entire population of an Italian region, we followed 1,293,941 subjects from the beginning of the pandemic to the current scenario of Omicron predominance (up to mid-February 2022). After an average of 277 days, we recorded 729 reinfections among 119,266 previously infected subjects (overall rate: 6.1‰), eight COVID-19-related hospitalizations (7/100,000), and two deaths. Importantly, the incidence of reinfection did not vary substantially over time: after 18-22 months from the primary infection, the reinfection rate was still 6.7‰, suggesting that protection conferred by natural immunity may last beyond 12 months. The risk of reinfection was significantly higher among females, unvaccinated subjects, and during the Omicron wave.
Keywords: COVID-19; Italy; Omicron variant; SARS-CoV-2; cohort study; reinfection.
Copyright © 2022 Flacco, Soldato, Acuti Martellucci, Di Martino, Carota, Caponetti and Manzoli.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.Front Public Health. 2023 Apr 4;11:1146059. doi: 10.3389/fpubh.2023.1146059. eCollection 2023. Front Public Health. 2023. PMID: 37081954 Free PMC article.
-
SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.Viruses. 2023 Jul 14;15(7):1551. doi: 10.3390/v15071551. Viruses. 2023. PMID: 37515237 Free PMC article.
-
Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.Euro Surveill. 2023 Mar;28(13):2200494. doi: 10.2807/1560-7917.ES.2023.28.13.2200494. Euro Surveill. 2023. PMID: 36995374 Free PMC article.
-
Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis.Eur J Clin Invest. 2022 Oct;52(10):e13845. doi: 10.1111/eci.13845. Epub 2022 Aug 8. Eur J Clin Invest. 2022. PMID: 35904405 Free PMC article. Review.
-
SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.Environ Res. 2022 Jun;209:112911. doi: 10.1016/j.envres.2022.112911. Epub 2022 Feb 8. Environ Res. 2022. PMID: 35149106 Free PMC article. Review.
Cited by
-
Low Risk of SARS-CoV-2 Reinfection for Fully or Boosted mRNA Vaccinated Subjects in Sicily: A Population-Based Study Using Real-World Data.Vaccines (Basel). 2023 Nov 26;11(12):1757. doi: 10.3390/vaccines11121757. Vaccines (Basel). 2023. PMID: 38140163 Free PMC article.
-
Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study.J Med Virol. 2022 Nov;94(11):5589-5592. doi: 10.1002/jmv.28026. Epub 2022 Aug 2. J Med Virol. 2022. PMID: 35879105 Free PMC article.
-
Epidemiological features and risk factors of SARS-CoV-2 reinfection: a retrospective cohort analysis in Xiamen, China.J Thorac Dis. 2025 Jul 31;17(7):4732-4745. doi: 10.21037/jtd-24-1703. Epub 2025 Jul 28. J Thorac Dis. 2025. PMID: 40809228 Free PMC article.
-
Effects of the second dose of COVID-19 vaccines in patients with autoimmune rheumatic diseases with hybrid immunity.Rheumatol Int. 2023 Mar;43(3):449-457. doi: 10.1007/s00296-022-05265-3. Epub 2022 Dec 30. Rheumatol Int. 2023. PMID: 36583801 Free PMC article.
-
Epidemiological Surveillance of SARSCov2 in β-Thalassemia Patients in the Last Two Years: Reinfection Rate, Insights and Future Challenges.Mediterr J Hematol Infect Dis. 2023 Jan 1;15(1):e2023007. doi: 10.4084/MJHID.2023.007. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 36660359 Free PMC article. No abstract available.
References
-
- To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. . Coronavirus disease 2019(COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. Clin Infect Dis. (2021) 73:e2946–51. 10.1093/cid/ciaa1275 - DOI - PMC - PubMed
-
- Helfand M, Fiordalisi C, Wiedrick J, Ramsey KL, Armstrong C, Gean E, et al. . Risk for reinfection after SARS-CoV-2: a living, rapid review for american college of physicians practice points on the role of the antibody response in conferring immunity following SARS-CoV-2 infection. Ann Intern Med. (2022) 175:547–55. 10.7326/M21-4245 - DOI - PMC - PubMed
-
- Krutikov M, Palmer T, Tut G, Fuller C, Shrotri M, Williams H, et al. . Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. Lancet Healthy Longev. (2021) 2:e362–70. 10.1016/S2666-7568(21)00093-3 - DOI - PMC - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous